173MO Immunological dynamics of HLA-II positive melanoma
Conclusions: Our transcriptomic results suggest that induction of anti-cancer immunity is possible in anti-PD-(L)1-refractory mUC, but in this setting a degree of preexisting immune activity might be necessary but not sufficient to mount a durable immune response upon anti-CTLA-4 treatment.Clinical trial identification: NCT03871036.
Authors
- Irene Lobón (ORCID: https://orcid.org/0000-0003-1170-9915)
- María Sánchez (ORCID: https://orcid.org/0000-0001-8425-4881)
- Marco Donia (ORCID: https://orcid.org/0000-0003-4966-9752)
- M. Presti
- Samra Turajlic (ORCID: https://orcid.org/0000-0001-8846-136X)
- Shaheen Khan (ORCID: https://orcid.org/0009-0008-7691-9810)
Institutions
- The Francis Crick Institute (GB)
- Herlev Hospital (DK)
- Gentofte Hospital (DK)
- Royal Marsden Hospital (GB)
Publication Details
- Journal
- Immuno-Oncology Technology
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1016/j.iotech.2024.100926
- Primary Topic
- Immunotherapy and Immune Responses
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Novo Nordisk
- H. Lundbeck A/S